IBDEI02R ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3170,2)
 ;;=^336480
 ;;^UTILITY(U,$J,358.3,3171,0)
 ;;=207.00^^29^257^3
 ;;^UTILITY(U,$J,358.3,3171,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3171,1,1,0)
 ;;=1^207.00
 ;;^UTILITY(U,$J,358.3,3171,1,8,0)
 ;;=8^AC Eryth & Erythroleuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,3171,2)
 ;;=^336866
 ;;^UTILITY(U,$J,358.3,3172,0)
 ;;=207.01^^29^257^1
 ;;^UTILITY(U,$J,358.3,3172,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3172,1,1,0)
 ;;=1^207.01
 ;;^UTILITY(U,$J,358.3,3172,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,3172,2)
 ;;=^267556
 ;;^UTILITY(U,$J,358.3,3173,0)
 ;;=207.02^^29^257^2
 ;;^UTILITY(U,$J,358.3,3173,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3173,1,1,0)
 ;;=1^207.02
 ;;^UTILITY(U,$J,358.3,3173,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,3173,2)
 ;;=^336481
 ;;^UTILITY(U,$J,358.3,3174,0)
 ;;=207.10^^29^257^9
 ;;^UTILITY(U,$J,358.3,3174,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3174,1,1,0)
 ;;=1^207.10
 ;;^UTILITY(U,$J,358.3,3174,1,8,0)
 ;;=8^Chr Erythremia w/o Remission
 ;;^UTILITY(U,$J,358.3,3174,2)
 ;;=^336867
 ;;^UTILITY(U,$J,358.3,3175,0)
 ;;=207.11^^29^257^8
 ;;^UTILITY(U,$J,358.3,3175,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3175,1,1,0)
 ;;=1^207.11
 ;;^UTILITY(U,$J,358.3,3175,1,8,0)
 ;;=8^Chr Erythremia in Remission
 ;;^UTILITY(U,$J,358.3,3175,2)
 ;;=^267558
 ;;^UTILITY(U,$J,358.3,3176,0)
 ;;=207.12^^29^257^7
 ;;^UTILITY(U,$J,358.3,3176,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3176,1,1,0)
 ;;=1^207.12
 ;;^UTILITY(U,$J,358.3,3176,1,8,0)
 ;;=8^Chr Erythremia in Relapse
 ;;^UTILITY(U,$J,358.3,3176,2)
 ;;=^336482
 ;;^UTILITY(U,$J,358.3,3177,0)
 ;;=207.20^^29^257^28
 ;;^UTILITY(U,$J,358.3,3177,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3177,1,1,0)
 ;;=1^207.20
 ;;^UTILITY(U,$J,358.3,3177,1,8,0)
 ;;=8^Megakaryocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,3177,2)
 ;;=^336868
 ;;^UTILITY(U,$J,358.3,3178,0)
 ;;=207.21^^29^257^27
 ;;^UTILITY(U,$J,358.3,3178,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3178,1,1,0)
 ;;=1^207.21
 ;;^UTILITY(U,$J,358.3,3178,1,8,0)
 ;;=8^Megakaryocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,3178,2)
 ;;=^267560
 ;;^UTILITY(U,$J,358.3,3179,0)
 ;;=207.22^^29^257^26
 ;;^UTILITY(U,$J,358.3,3179,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3179,1,1,0)
 ;;=1^207.22
 ;;^UTILITY(U,$J,358.3,3179,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3179,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,3180,0)
 ;;=207.80^^29^257^47
 ;;^UTILITY(U,$J,358.3,3180,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3180,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,3180,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3180,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,3181,0)
 ;;=207.81^^29^257^46
 ;;^UTILITY(U,$J,358.3,3181,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3181,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,3181,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,3181,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,3182,0)
 ;;=207.82^^29^257^45
 ;;^UTILITY(U,$J,358.3,3182,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3182,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,3182,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3182,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,3183,0)
 ;;=208.00^^29^257^21
 ;;^UTILITY(U,$J,358.3,3183,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3183,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,3183,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,3183,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,3184,0)
 ;;=208.01^^29^257^20
 ;;^UTILITY(U,$J,358.3,3184,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3184,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,3184,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,3184,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,3185,0)
 ;;=208.02^^29^257^19
 ;;^UTILITY(U,$J,358.3,3185,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3185,1,1,0)
 ;;=1^208.02
 ;;^UTILITY(U,$J,358.3,3185,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,3185,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,3186,0)
 ;;=208.10^^29^257^12
 ;;^UTILITY(U,$J,358.3,3186,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3186,1,1,0)
 ;;=1^208.10
 ;;^UTILITY(U,$J,358.3,3186,1,8,0)
 ;;=8^Chr Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3186,2)
 ;;=^336871
 ;;^UTILITY(U,$J,358.3,3187,0)
 ;;=208.11^^29^257^11
 ;;^UTILITY(U,$J,358.3,3187,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3187,1,1,0)
 ;;=1^208.11
 ;;^UTILITY(U,$J,358.3,3187,1,8,0)
 ;;=8^Chr Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,3187,2)
 ;;=^267569
 ;;^UTILITY(U,$J,358.3,3188,0)
 ;;=208.12^^29^257^10
 ;;^UTILITY(U,$J,358.3,3188,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3188,1,1,0)
 ;;=1^208.12
 ;;^UTILITY(U,$J,358.3,3188,1,8,0)
 ;;=8^Chr Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3188,2)
 ;;=^336486
 ;;^UTILITY(U,$J,358.3,3189,0)
 ;;=208.20^^29^257^53
 ;;^UTILITY(U,$J,358.3,3189,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3189,1,1,0)
 ;;=1^208.20
 ;;^UTILITY(U,$J,358.3,3189,1,8,0)
 ;;=8^Subacute Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3189,2)
 ;;=^336872
 ;;^UTILITY(U,$J,358.3,3190,0)
 ;;=208.21^^29^257^52
 ;;^UTILITY(U,$J,358.3,3190,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3190,1,1,0)
 ;;=1^208.21
 ;;^UTILITY(U,$J,358.3,3190,1,8,0)
 ;;=8^Subacute Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,3190,2)
 ;;=^267572
 ;;^UTILITY(U,$J,358.3,3191,0)
 ;;=208.22^^29^257^51
 ;;^UTILITY(U,$J,358.3,3191,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3191,1,1,0)
 ;;=1^208.22
 ;;^UTILITY(U,$J,358.3,3191,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3191,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,3192,0)
 ;;=208.80^^29^257^38
 ;;^UTILITY(U,$J,358.3,3192,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3192,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,3192,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,3192,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,3193,0)
 ;;=208.81^^29^257^37
 ;;^UTILITY(U,$J,358.3,3193,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3193,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,3193,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,3193,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,3194,0)
 ;;=208.82^^29^257^36
 ;;^UTILITY(U,$J,358.3,3194,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3194,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,3194,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,3194,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,3195,0)
 ;;=209.00^^29^257^25
 ;;^UTILITY(U,$J,358.3,3195,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3195,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,3195,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,3195,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,3196,0)
 ;;=209.01^^29^257^22
 ;;^UTILITY(U,$J,358.3,3196,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3196,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,3196,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,3196,2)
 ;;=^336490
 ;;^UTILITY(U,$J,358.3,3197,0)
 ;;=209.02^^29^257^24
 ;;^UTILITY(U,$J,358.3,3197,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3197,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,3197,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,3197,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,3198,0)
 ;;=209.03^^29^257^23
 ;;^UTILITY(U,$J,358.3,3198,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3198,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,3198,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,3198,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,3199,0)
 ;;=204.00^^29^258^1
 ;;^UTILITY(U,$J,358.3,3199,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3199,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,3199,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,3199,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,3200,0)
 ;;=204.01^^29^258^3
 ;;^UTILITY(U,$J,358.3,3200,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3200,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,3200,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,3200,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,3201,0)
 ;;=204.10^^29^258^5
 ;;^UTILITY(U,$J,358.3,3201,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3201,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,3201,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,3201,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,3202,0)
 ;;=204.11^^29^258^7
 ;;^UTILITY(U,$J,358.3,3202,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3202,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,3202,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,3202,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,3203,0)
 ;;=201.90^^29^258^11
 ;;^UTILITY(U,$J,358.3,3203,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3203,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,3203,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,3203,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,3204,0)
 ;;=202.00^^29^258^19
 ;;^UTILITY(U,$J,358.3,3204,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3204,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,3204,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,3204,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,3205,0)
 ;;=200.20^^29^258^16
 ;;^UTILITY(U,$J,358.3,3205,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3205,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,3205,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,3205,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,3206,0)
 ;;=202.10^^29^258^29
 ;;^UTILITY(U,$J,358.3,3206,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3206,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,3206,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,3206,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,3207,0)
 ;;=273.3^^29^258^21
 ;;^UTILITY(U,$J,358.3,3207,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3207,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,3207,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,3207,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,3208,0)
 ;;=203.00^^29^258^28
